Connect Biopharma stock rises after announcing plan to terminate ADR program

Connect Biopharma (CNTB) announced plans to terminate its American Depositary Receipts (ADR) program, opting instead for a direct listing of its ordinary shares on the Nasdaq Global Market by September 2, 2025. This strategic shift, which led to a 6.4% jump in CNTB stock, aims to enhance institutional visibility, eliminate ADR fees, and broaden the company's investor base, aligning with ongoing progress in its Phase 2 clinical development programs.

Analysis

Connect Biopharma (CNTB) has initiated a corporate restructuring to terminate its American Depositary Receipts (ADR) program and pursue a direct listing of its ordinary shares on the Nasdaq Global Market, a transition expected to be completed around September 2, 2025. This strategic move, which prompted a 6.4% rise in its stock price, is aimed at enhancing its profile as a U.S.-centric company, with management citing benefits such as increased institutional visibility, the elimination of ADR-related fees, and an expanded investor base. The company has timed this corporate action to align with progress in its clinical pipeline, specifically the Phase 2 development of its inflammatory disease candidate, rademikibart. While the company's management and the immediate market reaction are positive, an external analysis from InvestingPro's AI tool provides a tempering viewpoint, suggesting that CNTB may not be significantly undervalued compared to peers, indicating the fundamental investment case may be less compelling than the structural improvements imply.

Key Decisions for Investors

• View the planned transition from an ADR to a direct Nasdaq listing as a positive long-term catalyst for improved trading liquidity and institutional visibility, though it is a structural rather than a fundamental change.
• The primary value driver remains the clinical pipeline, so investors should closely monitor upcoming data from the Phase 2 trial of rademikibart, as trial outcomes will be more impactful to valuation than the listing change.
• Exercise caution regarding the stock's current valuation, as an external analysis suggests CNTB may not be significantly undervalued, implying the recent share price increase could have already incorporated the benefits of this corporate action.